HOW AI IS SUPERCHARGING DRUG DEVELOPMENT

Summary from the TLDR AI newsletter

AI is cutting preclinical costs and timelines in drug development by up to 70%, driving demand for advanced software and models. This could boost new drug program growth by over 10% in three to five years. However, AI has yet to yield an FDA-approved drug, raising concerns about its impact on patient treatment.